New Delhi, India, June 06, 2015 --(PR.com
)-- DelveInsight, the leading Business consultant and Market Research Firm is proud to announce the launch of its Report, PD-1 and PD-L1 inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2015. The report has provided the analysis on the worldwide therapeutic market of PD-1 and PD-L1 inhibitors. The Report has highlighted the development of combinations therapies with Immune-check point Inhibitors (PD-1 and PD-L1) and has provided information on ongoing collaborations for the development of combinations regimens.
PD-1 and PD-L1 targets are among the highly growing research fields in biopharmaceutical industries. DelveInsight PD-1 and PD-L1 Inhibitors Report has uncovered the potential of global PD-1 and PD-L1 market with insights into 2 marketed drugs and 38 pipeline drugs with approximate 245 active clinical studies. Report has covered the companies’ collaboration for the development of combination regimens with PD-1 and PDL-1 Inhibitors. There are total 28 companies found who have partnered with these Big Pharmas for 37 drugs or immunotherapies.
Report has also covered the Commercial Aspects such as the Current and Future Market, Barriers and challenges, SWOT analysis. Report has described the unmet need covered by PD-1 and PD-L1 inhibitors highlighting the side effects and toxic effects related to PD-1 and PD-L1 inhibitors which are the major concerns in the market for the usage of PD-1 and PD-L1 inhibitors.
DelveInsight is offering its PD-1 and PD-L1 Inhibitors Report at a price of USD 2,950.00 as a single user license, USD 5,900.00 as a site license and USD 8,850.00 as a Global/Enterprise License. These reports examine the entire market of PD-1 and PD-L1 inhibitors, current progress of competitive products, details of technologies, active ingredients and regulatory success of PD-1 and PD-L1 inhibitors and early market winners in place.
For more information, email at info@delveInsight.com